Headache 20 (8.1) 30 (12.2) 13 (8.0) 15 (9.2) Diarrhea 27 (10.9) 31 (12.6) 6 (3.7) 9 (5.5) Injection site nodule 26 (10.5) 25 (10.2) 6 (3.7) 11 (6.7)Nasopharyngitis 19 (7.7) 11 (4.5) 14 (8.6) 16 (9.8)Nausea 28 (11.3) 17 (6.9) 7 (4.3) 6 (3.7) Dyspepsia 18 (7.3) 8 (3.3) 8 (4.9) 3 (1.8) Constipation 21 (8.5) 8 (3.3) 3 (1.8) 4 (2.5)Back pain 6 (2.4) 14 (5.7) 7 (4.3) 5 (3.1) Arthralgia 13 (5.2) 3 (1.2) 5 (3.1) 3 (1.8) Hypertension 3 (1.2) 3 (1.2) 12 (7.4) 3 (1.8)Peripheral edema 0 (0) 1 (0.4) 12 (7.4) 1 (0.6) Data are n(%) of intent-to-treat population. 256 DIABETES CARE,VOLUME 35, F EBRUARY 2012 care.diabetesjournals.orgExenatide once-weekly monotherapyDownloaded from http://diabetesjournals.org/care/article-pdf/35/2/252/610738/252.pdf by guest on 17 January 2024